What makes a promising scientific asset truly fundable is whether it is operational, whether the path from milestone to milestone is robust. Signs of a Reliable Investment (Image Creation - ChatGPT) Designing Biotech Financial Models for Series B Success from WorldPharmaToday reframes what gets scrutinized in biotech financial models. Here are the key takeaways - … Continue reading A Molecule and a Dream: But is it Operational?
Uncategorized
Lilly acquires Ajax Therapeutics for $2.3B cash
Eli Lilly is acquiring Ajax Therapeutics by paying up to $2.3B cash, composed of an upfront and milestone payments. Image Credit: ChatGPT
Insidious CMC Risks in Regulatory Filings
As the FDA notes, many IND delays can be tied to CMC challenges. Quite often, warning signs are visible - analytical methods that are good enough but hard to scale- process steps that rely on the skills of an operator or one site- issues on stability or delivery that are shelved into future work.Such considerations … Continue reading Insidious CMC Risks in Regulatory Filings
Lilly Scoops up Adverum for $261M, with CVR and Loan
Adverum Biotechnologies (ADVM:NASDAQ) is being acquired by Eli Lilly and Company for $261M. While the acquisition proposes a transfer of $261M from Lilly to Adverum's stockholders, it is structured through a milestone payment and a bridge-loan. Payment Snapshot Upfront - $3.56/shareCVR - max $8.91/share contingent upon FDA approval and target sales of Ixo-vec.Bridge Loan - … Continue reading Lilly Scoops up Adverum for $261M, with CVR and Loan
Pfizer’s Big Beautiful Deal: Cheaper Drugs, US jobs, Tariff Relief
Pfizer has signed a momentous agreement with the US Federal government. Here's a snippet of what Pfizer gets and what we get (to be instituted in 2026): Quick Outline Pfizer will adhere to the most favored nation (MFN) pricing for all sales to Medicaid. So, Medicaid, usually the biggest customer to big pharma, will pay … Continue reading Pfizer’s Big Beautiful Deal: Cheaper Drugs, US jobs, Tariff Relief
BK talks Biopharm 